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DOI 10.1016/j.ccr.2012.03.041SUMMARYBasal-like breast cancers (BLBC) express a luminal progenitor gene signature. Notch receptor signaling
promotes luminal cell fate specification in the mammary gland, while suppressing stem cell self-renewal.
Here we show that deletion of Lfng, a sugar transferase that prevents Notch activation by Jagged ligands,
enhances stem/progenitor cell proliferation. Mammary-specific deletion of Lfng induces basal-like and
claudin-low tumors with accumulation of Notch intracellular domain fragments, increased expression of
proliferation-associated Notch targets, amplification of the Met/Caveolin locus, and elevated Met and
Igf-1R signaling. Human BL breast tumors, commonly associated with JAGGED expression, elevated MET
signaling, and CAVEOLIN accumulation, express low levels of LFNG. Thus, reduced LFNG expression
facilitates JAG/NOTCH luminal progenitor signaling and cooperates with MET/CAVEOLIN basal-type
signaling to promote BLBC.INTRODUCTION
Patients with BLBC show reduced survival compared to those
with more common luminal tumors, and this disease frequentlySignificance
Here we report that LFNG, which suppresses Jagged/Notch
basal-like tumors and deletion of this gene in the mouse mamm
cellular domain polypeptides, increases proliferation, and indu
fication of the Met/Caveolin gene locus. These mutations in
increased Notch pathway activation, as well as elevated Met a
BLBC may therefore benefit from combination therapy targeti
626 Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc.occurs in young patients, as well as in women with African
ancestry. Basal-like tumors express markers of myoepithelium,
but show a gene expression signature related to that of luminal
progenitor cells (Cheang et al., 2008; Lim et al., 2009; Perousignaling in vivo, is consistently expressed at a low level in
ary gland enhances accumulation of activated Notch intra-
ces basal-like mammary tumors in cooperation with ampli-
teract to promote a specific BLBC signaling network with
nd Igf-1R signaling. Patients withMET/CAV-overexpressing
ng Notch, MET, and IGF1R.
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progenitors may be the cell-of-origin for most BLBC (Molyneux
et al., 2010). In the mouse system, activated Notch1 can induce
commitment of mammary stem cells (MaSC) into luminal
progenitors, and promote proliferation of luminal progenitor cells
in vitro and in vivo (Bouras et al., 2008). Similarly in humans,
increased NOTCH3 expression and function can promote
luminal progenitor cell fate specification, at least in vitro (Raouf
et al., 2008).
On the basis of studies with the Mouse Mammary Tumor Virus
(MMTV), which can induce mammary tumor formation through
insertional activation of Notch genes, a role for Notch signaling
in human breast cancer was anticipated (Callahan and Smith,
2000). Most human breast tumors express Notch ligands and
receptors (Parr et al., 2004; Pece et al., 2004; Reedijk et al.,
2005; Stylianou et al., 2006). High-level expression of the
JAGGED1 ligand, as well as NOTCH1 and/or NOTCH3, is asso-
ciated with poor overall survival (Reedijk et al., 2005). Recent
studies reveal that signaling through multiple Notch receptors
activates proliferation and/or survival of breast cancer cells
(Harrison et al., 2010; Haughian et al., 2012; Osipo et al., 2008;
Sansone et al., 2007; Yamaguchi et al., 2008). Interestingly,
JAGGED-dependent Notch pathway activation has been associ-
ated with triple negative (ERa, PR, and HER2) tumors, and
specifically with basal-like tumors and cell lines (Cohen et al.,
2010; Dong et al., 2010; Haughian et al., 2012; Lee et al.,
2008a, 2008b; Leong et al., 2007; Reedijk et al., 2008; Sansone
et al., 2007).
Met, a cell surface tyrosine kinase receptor involved in
epithelial-mesenchymal transition, is frequently expressed at
high levels in BLBC (Elsheikh et al., 2008; Gastaldi et al.,
2010; Lu et al., 2008; Ponzo and Park, 2010; Ravid et al.,
2005; Salani et al., 2008; Savage et al., 2007), and many
basal-like tumors show elevated Met signaling (Hochgra¨fe
et al., 2010). In addition, Caveolin1 and 2, which facilitate
Igf-1R signaling, are also overexpressed (Elsheikh et al.,
2008; Gastaldi et al., 2010; Lu et al., 2008; Ponzo and Park,
2010; Ravid et al., 2005; Salani et al., 2008; Savage et al.,
2007). Interestingly, the genes coding for MET, CAV1, and
CAV2 are located in the same region of Chromosome 7q31
and this locus is overexpressed in many BLBC (Elsheikh
et al., 2008; Gastaldi et al., 2010; Ponzo and Park, 2010;
Savage et al., 2007).
Fringe proteins are N-acetylglucosamine transferases that
modify Notch receptors to control ligand-mediated activation
(Haines and Irvine, 2003). These proteins enhance Notch activa-
tion by Delta-family ligands, while inhibiting Notch activation by
Serrate/Jagged ligands (Haines and Irvine, 2003). Lfng, one of
three Fringe genes in mammals, controls Notch signaling in
many developing tissues (Cohen et al., 1997; Johnston et al.,
1997). Interestingly, LFNG is expressed at high levels in MaSC
and/or bipotent progenitor cells of the human breast (Raouf
et al., 2008). However, its role in the regulation of Notch signaling
of the developing or adult mammary gland remains unknown, as
is its potential for restricting Notch-dependent oncogenic
signaling in this context. In this study, we used conditional
mutant mice to define the function of Lfng in mammary epithe-
lium. In addition, we tested for its expression and potential role
in human breast cancer.RESULTS
A Lfng Expression Boundary in Mammary Development
To define where and when Notch is activated in the developing
mammary gland, we used LacZ knock-in mice for various Notch
pathway genes. Typically, boundaries between Fringe-express-
ing cells and nonexpressing cells are sites of consequential
Notch signaling (Irvine, 1999). Therefore, we examined Lfng
expression by performing X-gal staining on mammary glands
from six-week-old LfngLacZ/+ virgin females (Zhang and Gridley,
1998). Interestingly, Lfng expression was restricted to basal
cells, in particular to cap cells of terminal end buds (TEBs) (Fig-
ure 1A), which have MaSC activity (Bai and Rohrschneider,
2010). This result is consistent with studies on cells purified
from the humanmammary gland, which show that LFNG expres-
sion is > 20-fold enriched in stem and/or bipotent progenitor
cells as compared with luminal restricted progenitors (Raouf
et al., 2008). Two Notch ligands,Dll1 and Jagged1, show distinct
expression at this stage. Weak X-gal staining from a Dll1lacZ/+
allele (Hrabĕ de Angelis et al., 1997) was observed in cap cells
of the mammary TEB. In contrast, their basally located myoepi-
thelial descendants showed intense staining. X-gal staining in
pubescent Jagged1bGeo/+ (Xu et al., 2010) mice was strongest
in stromal cells surrounding each TEB (Figure 1A).
In mature adults, after TEB regression, LfnglacZ expression was
barely detected, while Dll1lacZ expression remained strong in
myoepithelial cells. Interestingly, Jagged1 expression switched
from stroma to myoepithelium in the mature gland (Figure 1A).
JAGGED1 expression is also high in basal cells of the mature
human gland (Reedijk et al., 2005). Next, we used antibodies to
stain for Notch1 and Notch4, which were expressed at low levels
in luminal and basal cells, respectively (Figure S1A available
online). Using b-Geo/+ knock-in mice (Xu et al., 2010), Notch3
expression was found to be high in body cells of the TEB, as well
as in luminal epithelial cells of mature ducts, whereas Notch2
expression was strong in stroma and weak in epithelium (Fig-
ure S1B). These data are consistent with recent Notch ligand and
receptor expressionanalysisby rtPCRand immunohistochemistry
(Bouras et al., 2008; Raafat et al., 2011; Raouf et al., 2008).
Lfng Controls Notch Activation and Suppresses
Mammary Epithelial Proliferation
Fringe controls Notch activation at compartment boundaries in
the developing fruit fly (Irvine, 1999). Our expression analysis in
themammary gland reveals a similar boundary at the TEB-ductal
junction, where Lfng may differentially regulate Notch activation
induced by Dll1 and/or Jagged1. To define Lfng function in this
context, we analyzed mammary development in Lfng mutant
mice. Whole-mount analysis showed evidence of epithelial
hyperplasia in virgin mammary glands from Lfng mutants (Fig-
ure 1B). Sections from mutant and control glands were stained
with antibodies against luminal and basally restricted cytokera-
tins, keratin 8 (K8) and 14 (K14), respectively.Mostmutant glands
showed decreased K8 expression in body cells of the TEB. Also,
multiple layers of K14+ basal cells were observed in some loca-
tions. Cells did not co-express K8 and K14 in wild-type ormutant
glands during puberty (Figure 1C). We next tested for altered cell
proliferation by staining for Ki67. Indeed, Lfng mutant glands
showed increased cell proliferation in mature ducts (Figure 1D).Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc. 627
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Figure 1. Lfng Is Expressed in Mammary Basal Cells and Its Deletion Causes Increased Proliferation and Expansion of the CD24+
CD49fHiCD61+Sca1– Population in the Pubescent Mammary Gland
(A) Expression of Lfng,Dll1, and Jagged1 in themousemammary gland. Shown are representative photomicrographs of whole-mount (left column) and sectioned
X-Gal staining of mammary glands from LfngLacZ/+,Dll1LacZ/+, and Jagged1bGeo/+ virgin mice at 6 weeks and 5months of age. Sections for the TEBs are shown in
the second column from left.
(B) Mammary hyperplasia in the Lfng/mutant. Shown are representative photomicrographs of whole-mount mammary glands from 6- and 12-week-old virgins.
(C) Representative photomicrographs of anti-K8, -K14 immunofluorescence staining in mammary sections from 6-week-old virgins of Lfng+/+ and Lfng/mice.
TEBs and ducts are shown in upper and lower panels, respectively.
(D) Ductal elongation at 6 weeks old, measured as the distance between the lymph node and the ductal front line normalized to the distance between the lymph
node and the end of the fat pad, are presented asmean values ± standard error. *p < 0.05. Note, the Lfng null allele was generated through expression of Cre in the
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Lfng Suppresses Basal-like Breast Tumor FormationFringe proteins control Notch signaling by enhancing Delta-
while inhibiting Serrate/Jagged-mediated activation (Haines
and Irvine, 2003). Based on high-level Lfng expression in cap
cells of the TEB, and the known cell autonomous function of
Fringe proteins (Panin et al., 1997), Lfng likely facilitates Dll-
mediated Notch signaling or blocks Jagged1-mediated Notch
activation in MaSC and/or bipotential progenitors of the cap
layer. The Transgenic Notch Reporter (TNR) mouse has an arti-
ficial Notch-responsive promoter with multiple RBPJk-binding
sites regulating expression of eGFP (Duncan et al., 2005).
This mouse has been used successfully to study Notch/p63
interaction in the developing mammary gland (Yalcin-Ozuysal
et al., 2010). Therefore, to test for alterations in Notch signaling
associated with Lfng deletion, we crossed TNR reporter mice
with Lfng mutants. To follow Notch signaling at multiple levels
within the developmental hierarchy, lineage-depleted mam-
mary epithelial cells were stained for surface markers CD24,
CD49f, CD61, and Sca1. Remarkably, Lfng null glands showed
a more than 2-fold (2.37 ± 0.07, p < 0.05) enrichment of
CD24+CD49fhi cells, a population known to contain mammary
stem/early progenitor cells (Figure 1E). We gated on this pop-
ulation and found that most cells were CD61+Sca1, charac-
teristic of MaSC (Visvader, 2009) (Figure 1E). In some cases
this was associated with decreased numbers of CD24hiC49f+
CD61+ luminal progenitor cells (Figure 1E). Thus, our flow
cytometry analysis indicated that deletion of Lfng caused
accumulation of stem/bipotent progenitor cells, likely at the
expense of luminal progenitor cells in the developing mam-
mary gland. Interestingly, Lfng/; TNR mutants showed
40% decrease in GFP+ lineage-depleted mammary epithelial
cells as compared to Lfng+/+ or +/; TNR controls (Figure S1C).
Specifically, in mutant mice, fewer cells with active Notch sig-
naling were observed in MaSC/early progenitor-containing
(CD24+CD49fhi) and luminal progenitor-containing (CD24hi
CD49f+) compartments (Figure S1D) (Shackleton et al.,
2006; Stingl et al., 2006). Thus, deletion of Lfng leads to
decreased Notch signaling in MaSC and progenitors in puberty
(likely as a result of reduced Dll1-mediated Notch activation at
this stage), and is associated with expansion of the immature
cell compartment. These data are consistent with those of
Bouras et al., who showed that shRNA-mediated knock-
down of RBPJk, and thus disruption of canonical Notch
signaling, caused expansion of the CD24+CD29hi compartment
(note: this is the same as the CD24+CD49fhi compartment),
and promotion of MaSC self-renewal (Bouras et al., 2008).
Lfng Is a Suppressor of Basal-like Tumor Formation
in the Mouse Mammary Gland
Next, we tested for Lfng function by generating a Cre-conditional
Lfngmutant mouse (Xu et al., 2010). This mouse was crossed to
MMTV-Cre line A, which shows robust expression in mammarygermline of female Lfngflox/+; MMTV-Cre mice. Increased mammary epithelial p
representative photomicrographs of anti-Ki67 immunostaining in mammary secti
epithelial cells in TEBs or in ductal areas, presented as mean values ± standard
(E) Representative flow cytometry analyses of lineage-depleted mammary cells f
old. Shown are CD24/CD49f plots and Sca-1/CD61 plots on populations I, II, III
Scale bars correspond to 1 mm in left panels of (A), 5 mm in (B), and 50 mm in al
See also Figure S1.epithelium (Wagner et al., 1997). Many Lfngflox/flox; MMTV-Cre
mutant mice developed mammary tumors starting at 10 months
of age (Figure 2A). Histological analysis revealed three types of
Lfng mutant tumors: approximately 60% showed glandular
differentiation (type I); one-third mainly consisted of mesen-
chymal/spindle-shaped cells (type II); and about 5% had areas
containing multinucleated giant cells (type III) (Figure 2B). All
three histological types were triple-negative (ERa-, PR-, Her2/
Neu-negative) (Figure 2C and data not shown), and highly prolif-
erative (Figure 2D). Interestingly, tumors of all three types had
cells co-expressing luminal (K8) and basal markers (K14).
Notably, type I tumors contained a higher percentage (75.3%
versus 16.8% in type II) of cells expressing one or both
lineage-specific keratin (Figure 2E).
Next, we used transcriptional profiling to define molecular
subtype for 11 Lfng mutant tumors (Herschkowitz et al., 2007).
Interestingly, in unsupervised cluster analysis, these tumors
grouped with basal-like and claudin-low models but were other-
wise quite unique. Specifically, six type I tumors clustered
together with Brca1/p53 tumors, DMBA-induced tumors and
Wap-SV40T121-induced tumors, all of which are related to
BLBC, whereas five spindle/EMT or type II Lfng mutant mam-
mary tumors clustered nearby, together with DMBA-induced
spindle tumors as well as with Brca1/p53 tumors, which have
previously been identified as claudin-low (Herschkowitz et al.,
2007) (Figures 3A and 3B). The claudin-low signature is related
to that observed in MaSCs (Hennessy et al., 2009). Interestingly,
many mouse mammary tumors that were induced by activated
Met cluster with similar basal-like mouse models (Ponzo et al.,
2009). We also performed enrichment map analysis to identify
differentially expressed gene sets in Lfngflox/flox; MMTV-Cre
mammary tumors as compared to those expressed in other
mouse breast cancer models. Interestingly, gene sets implicated
in leukocyte activation and proliferation, inflammation, cytokine
and chemokine signaling, as well as extracellular matrix remod-
eling were overrepresented in Lfng mutant tumors (Figure 3C
and Table S1).
We next analyzed tumors by flow cytometry. Lfng mutant
tumors were composed of cells with marker profiles that were
distinct from profiles seen in the normal mammary gland. As dis-
cussed previously, the characteristic mammary epithelial profile
includes CD24+CD49fhi cells enriched for MaSC/bipotent pro-
genitors, CD24hiCD49f+ cells that are enriched for luminal
progenitors, with a third compartment of CD24CD49f cells.
In contrast, type I Lfngmutant tumors had an increased fraction
of CD49f+ cells, approximately half of which expressed CD24
(Figure 4A). Most of the CD49f+ cells also expressed CD61,
with lower expression of Sca1 noted. Finally, there was an
increased number of CD24+CD61+ cells and most of these
were CD49f+Sca1, suggesting that a luminal progenitor-like
compartment is expanded in these tumors (Figures 4B androliferation in Lfng/ compared with control Lfng+/+ littermates. Shown are
ons same as (C). Numbers of Ki67+ cells are normalized to the total number of
error. **p < 0.005.
rom Lfng/; TNR mutants compared with Lfng+/+; TNR littermates at 6 weeks
gated as in CD24/CD49f plots.
l others.
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Figure 2. Deletion of Lfng Induced Mammary Tumors in Mice
(A) Kaplan-Meier mammary tumor-free survival curve for control Lfngflox/flox and Lfngflox/flox; MMTV-Cre conditional mutant mice.
(B) Representative photomicrographs of H&E stained sections showing three histological types of Lfngflox/flox; MMTV-Cre mammary tumors.
(C) Anti-ERa immunostaining on twomain types of Lfngflox/flox; MMTV-Cremammary tumors. n: normal tissue; t: tumor. Note positive ERa staining in normal tissue
adjacent to the tumor.
(D) Representative photomicrographs and quantification of anti-Ki67 immunostaining on two main types of Lfngflox/flox; MMTV-Cre mammary tumors. Data are
derived from two sections in each of three Type I and Type II tumors presented as mean values ± standard error.
(E) Representative photomicrographs of anti-K8, -K14 immunofluorescence staining on three types of Lfngflox/flox; MMTV-Cremammary tumors. Arrows point to
cells showing co-expression of K8 and K14.
Scale bars correspond to 100 mm in (B), 50 mm in (C), (D) and (E).
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cence-activated cell sorting was used to fractionate tumor cells
and to test for tumor initiating activity. Specifically, we separated
type I tumors into three distinct populations (CD24+CD49f+,630 Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc.CD24CD49f, and CD24CD49f+) and injected matrigel
suspensions of each into mammary fat pads of FVB recipient
mice. Most tumor initiating activity was found within the CD24+
CD49f+ luminal progenitor-like population (Figure 4C).
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Figure 3. Lfngflox/flox; MMTV-Cre Tumors Cluster with Basal-like and Claudin-Low Mouse Mammary Tumor Models
(A) Overview of expression of reference genes in tumors from various mouse models of breast cancer, including 11 tumors from Lfngflox/flox; MMTV-Cre mice.
Colored bars at left correspond to regions shown in (B).
(B) Expression of selected genes representing the Claudin gene cluster, luminal gene cluster, proliferation-associated gene cluster, CK14 basal-like gene cluster,
CK5 basal-like gene cluster, and EMT gene cluster. Expression data from type I and type II Lfngflox/flox; MMTV-Cre tumors are contained within yellow boxes.
Clusters of tumor models are highlighted at the bottom. DMBA, 7,12-dimethylbenz[a]-anthracene.
(C) Enrichment map for gene sets over-represented in list of genes that are differentially expressed comparing Lfngflox/flox; MMTV-Cremousemammary tumors to
other mouse models of breast cancer.
See also Table S1.
Cancer Cell
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pressed high levels of CD61, contained Aldh1+ cells, and ex-
pressed low levels of Gata3 (Figures 4D and S2B) (Ginestier
et al., 2007; Visvader, 2009; Visvader and Smith, 2011). Type II
tumors show fewer CD61+ cells, and were almost completelynegative for Aldh1. However, Vimentin and Twist, two markers
associated with EMT, were broadly expressed in type II, but
not type I, tumors (Figure 4D). Phospho-Akt, a marker of PI3K
signaling, was evident in type II tumors and at a somewhat lower
level in type I tumors (Figure 4D). Thus, based on histology,Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc. 631
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Figure 4. Flow Cytometry and Immunohistological Analysis of Lfngflox/flox; MMTV-Cre Tumors
(A) Representative flow cytometry contour plots for lineage-depleted mammary tumor cells compared with non-tumor lineage-depleted mammary cells from
a Lfngflox/flox; MMTV-Cre mouse. Shown are CD24/CD49f, CD61/CD49f, and Sca1/CD49f plots from a Type I tumor.
(B) Additional analysis of the flow cytometry data as shown in (A): CD24/CD61plots and Sca1/CD49f plots on the CD24+CD61+ populations as gated in the upper
panels.
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type I lesions were basal-like tumors with features of luminal
progenitors (Cheang et al., 2008; Perou and Børresen-Dale,
2011), and type II were similar to claudin-low tumors with EMT-
like features, a phenotype associated with MaSC-like cells (Car-
diff, 2010; Taube et al., 2010).
Because Lfng regulates Notch signaling in mammary epithe-
lium as shown previously, we tested for altered expression of
known Notch target genes in these tumors. Indeed, all 11
Lfngflox/flox; MMTV-Cre mammary tumors showed reduced
expression of Hey1, Hey2, and Notch3, but elevated expression
of Dll4 and the Notch target genes uPA, c-Myc, and Cyclin D1
(Cohen et al., 2010; Klinakis et al., 2006; Shimizu et al., 2011)
(Figure 5A). As for other models, high-level expression of Hey1,
Hey2, Notch3, c-Myc, Cyclin D1, and Notch4 (Int3), as well as
low-level expression of p63 and Dll1 was observed in tumors
induced by activated Notch4 (Wap-Int-3). In contrast, low-level
expression of Hey1, Notch1, c-Myc (endogenous), Cyclin D1,
p63, and Dll1 was observed in MMTV-Myc tumors. Finally,
Hey1 was highly expressed in Her2/Neu and Polyoma Middle
T-induced tumors (Figure 5A).
To directly test for activation of Notch signaling in
Lfngflox/flox;MMTV-Cremammary tumors, we performed western
blot analysis using antibodies that recognize N-terminal
sequences of cleavage-generated intracellular domain (ICD)
fragments from Notch1 and 2. Indeed, higher levels of Notch1ICD
and Notch2ICD were present in Lfngmutant tumors as compared
to control non–tumor-bearing glands from the same animal (Fig-
ure 5B). Specific antibodies to detect murine Notch3ICD and
Notch4ICD are currently unavailable; however, expression and
processing of both proteins were changed in Lfngmutant tumors
(Figure S3). For Notch4, increased accumulation of a C-terminal
fragment consistent with Notch4ICD was observed (Figure S3).
Finally, Jagged1 protein was expressed in Lfng mutant tumors,
as were the protein products of Notch target genes, Cyclin D1
and c-Myc (Figure 5C). Thus, Lfng gene deletion results in Notch
activation in these tumors, and is consistent with induction of
Jagged/Notch target genes, CyclinD1 and c-Myc.
Met/Caveolin Gene Amplification and Signaling in Lfng
Mutant Tumors
Next, to identify cooperative events in Lfng mutant tumors, we
performed aCGH (array comparative genomic hybridization) on
DNA isolated from 5 Lfng conditional mutant tumors as
compared to non-tumor DNA isolated from control tissue. While
copy number gains and losses were noted in many regions
across the genome, the only common abnormality involved
amplification of a small locus at chromosome 6A2 (Figures S4A
and S4B). This was observed in 4 out of 5 tumor samples, the
exception being a Lfngflox/+;MMTV-Cre mammary tumor. The
overlapping region with copy number gains in each of the four
tumors contained 13 genes including the tyrosine kinase Met,(C) Limiting dilution transplantation assay on CD24+CD49f+, CD24CD49f and C
two independent experiments using two donors of type I tumor. TIC: Tumor-Ini
(CD24+CD49f+ versus CD24CD49f+)
(D) Representative photomicrographs of anti-Aldh1, anti-CD61, anti-Vimentin, an
MMTV-Cre mammary tumors. Scale bars correspond to 50 mm.
See also Figure S2.and neighboring Cav1 and 2 genes (Figure 6A). This locus is
amplified and/or overexpressed in BLBC in humans and in
mammary tumors from Brca1d11/co; p53+/; MMTV-Cre mice
(Savage et al., 2007; Smolen et al., 2006). To determine which,
if any, of these genes were overexpressed in Lfng mutant
tumors, we screened our transcriptional profiling data for
expression of genes within this region. Indeed, expression of
several, including Met, Cav1 and 2, was significantly elevated
in Lfng mutant tumors (Figure 6B). Interestingly, high-level MET
expression has been noted in aggressive human breast cancer,
particularly in breast tumors with EMT features (Gastaldi et al.,
2010; Ponzo and Park, 2010), and expression of oncogenic
Met can induce basal-like mammary tumors in transgenic mice
(Graveel et al., 2009; Ponzo et al., 2009). We next used western
analysis to test for elevated Met accumulation and activation in
Lfngmutant tumors. As shown in Figure 6C, Lfngmutant tumors
showed dramatically increased Met expression and activation.
Overexpressed Met could still depend on HGF ligand for activa-
tion. Indeed, Hgfa was identified as overrepresented in gene
expression signatures from Lfng mutant tumors in comparison
to other mouse models of breast cancer analyzed (Table S1),
and HGFa expression was detected by western analysis of
Lfngmutant tumors (data not shown). Next, we analyzed Caveo-
lin 1/2 expression in Lfng tumors. In the normal mammary gland,
Caveolin 1 is very highly expressed in endothelial cells, adipo-
cytes, and basally localized myoepithelium. High-level expres-
sion was also seen in type I and II tumor cells (Figure 6D). We
analyzed Caveolin 2 expression by western blot, and in each
case, it was elevated in tumor cells in comparison to nontumo-
rousmammary tissue from the same animal (Figure 6E). Caveolin
expression has been linked to enhanced Insulin and Igf-1R
signaling (Lu et al., 2008; Ravid et al., 2005; Salani et al., 2008),
and elevated Igf-1R signaling can induce mammary tumors in
mice (Jones et al., 2007). We therefore analyzed InsR and
Igf-1R signaling at the level of Irs1/2 tyrosine phosphorylation.
Indeed, Irs tyrosine phosphorylation was elevated in Lfngmutant
mammary tumors (Figure 6E). Thus, Lfng mutant tumors have
selected for activation of receptors that are more highly ex-
pressed or active in basal cells (Hvid et al., 2011; Niranjan
et al., 1995).
Low-Level LFNG Expression Is a Hallmark of Basal-like
Breast Cancer in Humans
Because deletion of Lfng caused basal-like and claudin-low
mammary tumors in mice, we analyzed LFNG expression in
human breast cancer. First, we screened publically available
gene expression data from 676 human breast cancers with
linked clinical-pathological information. Interestingly, reduced
LFNG expression was associated with high tumor grade, with
ERa/PR/HER2 triple-negative status, and most significantly,
with the basal-like molecular subtype (Figures S5A and S5B).
To the contrary, elevated LFNG expression was noted in ER+D24CD49f+ tumor cells as gated in a CD24/CD49f plot. Data are derived from
tiating Cells. *p = 0.0307 (CD24+CD49f+ versus CD24CD49f), **p = 0.0155
ti-Twist and anti-Phospho-Akt immunostaining in two main types of Lfngflox/flox;
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Relative to median expression
A
B C
Figure 5. Dysregulation of Notch Signaling Pathway and Downstream Target Genes in Lfngflox/flox; MMTV-Cre Tumors
(A) Expression of selected Notch signaling pathway and downstream target genes in tumors from various mouse models of breast cancer, including 11 tumors
from Lfngflox/flox; MMTV-Cre mice. Expression data from type I and type II Lfngflox/flox; MMTV-Cre tumors are contained within yellow boxes. Genes with lower
expression in Lfngflox/flox; MMTV-Cre tumors are highlighted in green, with higher expression in red. Clusters of tumor models are highlighted at the bottom.
DMBA, 7,12-dimethylbenz[a]-anthracene.
(B) Western blot analysis of cleaved Notch1 and cleaved Noch2 in mammary tumors (t) and non-tumor mammary tissue (n) from Lfngflox/flox; MMTV-Cre mice
(#1981, #1982, #8802), as well as in non-tumor mammary tissues from 18-month old Lfngflox/flox and Lfngflox/flox; MMTV-Cre littermate mice. b-actin served as
loading control.
(C) Representative photomicrographs of anti-Jagged1, anti-Cyclin D1 and anti-C-Myc, immunostaining in two main types of Lfngflox/flox; MMTV-Cre mammary
tumors. Scale bars correspond to 50 mm.
See also Figure S3.
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Lfng Suppresses Basal-like Breast Tumor Formationtumors and HER2+ tumors (Figures S5A and S5B). Nevins and
colleagues have recently identified gene expression signatures
for activation of signaling pathways in breast cancer (Gatza
et al., 2010).We therefore tested for activation of these pathways
in relation to LFNG gene expression. Several oncogenic path-
ways including those associated with a high rate of proliferation
(Myc and E2F1), as well as stem cell signaling (b-catenin), show
increased activity in tumors with low LFNG expression, whereas
the p53 pathway activity is significantly depressed in LFNGlow
tumors (Figure S5B). As Met was amplified and overexpressed
in our Lfng mutant mammary tumors, we also tested for MET
expression. As previously noted, basal-like and triple negative
breast tumors expressed elevated levels of MET (Figure S5B
and S5C) (Graveel et al., 2009; Ponzo et al., 2009). Perhaps not
surprisingly, low LFNG expression was correlated with elevated
MET levels (Figure S5C).
Finally, a number of studies have highlighted a potential role
for Notch receptor signaling in human breast cancer. Therefore,
we performed cluster analysis on the UNC publicly available
microarray data set (UNC337, GSE18229), and evaluated
expression of NOTCH pathway genes in each subtype (Prat
et al., 2010). Once again, low-level LFNG expression was noted
in basal-like tumors from this cohort, and also in a group of clau-
din-low tumors (Figures 7A and 7B).HES1, and to a lesser extent
HEY1, showed reduced expression in a subset of basal tumors
(Figure 7A). In contrast, c-Myc and NOTCH1 expression were
elevated in BLBC (Figures 7A and 7B). Thus, LFNG expression
is consistently low in human basal-like and a subset of claudin-
low breast cancers. These data help explain how Jagged-medi-
ated Notch activation stimulates proliferation (Cohen et al., 2010)
aswell as invasion (Shimizu et al., 2011) of BLBC and other triple-
negative breast tumors.
DISCUSSION
With the discovery of Notch4 as a target in MMTV-induced
mammary tumor formation, it became clear that elevated Notch
signaling was oncogenic in mammary epithelium (Callahan and
Smith, 2000). Indeed, translocations that activate NOTCH1 or 2
have been identified in some triple-negative breast cancers
and cell lines (Robinson et al., 2011). In this study we have iden-
tified a role for Lfng deletion (mouse) or downregulation (human)
in BLBC, associated with activation of NotchICD accumulation
and induction of oncogenic Notch target gene expression.
Multiple Notch receptors are expressed in the mammary gland
and several of these are believed to function in breast cancer
(Harrison et al., 2010; Haughian et al., 2012; Osipo et al., 2008;
Sansone et al., 2007; Yamaguchi et al., 2008). Based on accu-
mulation of luminal progenitor-like cells in Lfng mutant basal-
like tumors, our data reinforce the finding that elevated Notch
signaling enhances proliferation of this compartment (Bouras
et al., 2008). Interestingly, a low level of LFNG is observed in
the vast majority of BLBCs (Figure 7). It will be important to see
how these tumors compare in phenotype to the small fraction
of triple-negative tumors with Notch-activating translocations
(Robinson et al., 2011).
Deletion of Lfng in our conditional mutant mice results in
reduced expression of the Notch reporter gene during puberty.
Based on the known function of Fringe proteins to enhanceDelta ligand–mediated signaling, these data suggest that Dll1,
expressed in myoepithelial cells, functions to activate Notch in
Lfng-expressing MaSCs or bipotent progenitors. In adults,
Jagged1 expression is enhanced within the epithelial compart-
ment (Figure 1) (Reedijk et al., 2005). Loss of Lfng in this setting
would be expected to increase Jagged/Notch signaling and to
induce luminal cell fate commitment as well as proliferation of
luminal progenitors (Bouras et al., 2008). It is this effect, in older
animals, that is likely responsible for establishing both lineage
bias and progenitor compartment expansion to set the stage
for transformation.
Human BLBCs contain dozens of mutations that presumably
cooperate to transform mammary progenitor cells (Ding et al.,
2010). Recent data indicate that cooperative interactions occur
between mutations in a number of tumor suppressors, including
RB1, TP53, BRCA1, PTEN, and PTPN12 (Carey et al., 2010;
Foulkes et al., 2010; Herschkowitz et al., 2008; Holstege et al.,
2010; Jiang et al., 2010, 2011; Kobayashi, 2008; Rakha et al.,
2008; Saal et al., 2008; Sun et al., 2011). Despite this, it has
not been clear how oncogenic pathways interact to control
lineage in basal tumors. As a first step to define cooperative
pathways in Lfng mutant tumors, we performed aCGH analysis
and found Met/Cav gene amplification and enhanced signaling
to represent a common event in this context. Indeed, low-level
LFNG expression and elevated MET signaling are both associ-
ated with BLBC in humans (Gastaldi et al., 2010; Ponzo and
Park, 2010). Interestingly, this same amplicon is selected for in
brain tumors that occur in Pten/p53 conditional mutant mice,
but not in brain tumors from mice with conditional deletion of
Pten, p53, and Rb (Chow et al., 2011), suggesting that Met/
Cav gene amplification/overexpression may perform similar
oncogenic functions as Rb gene deletion, an event also associ-
ated with BLBC in humans and mice (Herschkowitz et al., 2008;
Jiang et al., 2010). The consistent selection for amplification of
theMet/Cav locus in Lfngmutant tumors is striking, and speaks
to an emerging concept in cancer whereby genes that function
synergistically to enhance signaling through a specific onco-
genic signaling pathway will frequently be co-selected during
tumor formation or progression. For example, the chromosome
17q amplicon in HER2+ breast tumors encodes the HER2
receptor and also the Grb7 adaptor protein, which binds to
HER2 protein to facilitate signal transduction (Andrechek et al.,
2003; Stein et al., 1994). In addition, the 9p24 amplicon associ-
ated with mediastinal B cell lymphoma contains several genes
that interact synergistically to enhance IL-13 signaling (Rui
et al., 2010). The consistent selection for amplification of the
Met/Cav gene locus in Lfng mutant tumors, and common over-
expression of this locus in humanBLBC, also leads to synergistic
interactions. As depicted in Figure 8, Lfng gene loss or reduced
expression of LFNG in human tumors cooperates with Met and
Cav1/2 gene amplification at multiple levels. First, elevated
Notch signaling as a result of decreased Lfng function, promotes
specification and proliferation of luminal progenitors (Bouras
et al., 2008). In addition,Met amplification would naturally result
in elevated Met signaling. This effect should be enhanced
through absence of Hes/Hey-mediated silencing of the Met
gene promoter (Stella et al., 2005). Finally, Caveolin1/2 overex-
pression would be expected to enhance signaling through the
insulin receptor and/or Igf-1R (Lu et al., 2008; Ravid et al.,Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc. 635
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Figure 6. Met/Caveolin Amplicon and Signaling of Met and IgfR in Lfngflox/flox; MMTV-Cre Mammary Tumors
(A) aCGH analysis of DNA isolated from four Lfngflox/flox; MMTV-Cre mouse tumors and one Lfngflox/+; MMTV-Cre tumor showing a commonly amplified locus
among all four Lfngflox/flox; MMTV-Cre tumors on chromosome 6. Red bar corresponds to the overlapping region containing 13 genes.
(B) Expression of the commonly amplified genes as shown in (A) in 11 Lfngflox/flox; MMTV-Cre tumors in comparisonwith expression of these genes in other mouse
models of breast cancer. Expression data from type I and type II Lfngflox/flox; MMTV-Cre tumors are contained within yellow boxes.
(C) Western blot analysis of Met and phospho-Met in mammary tumors (t) and non-tumor mammary tissue (n) from Lfngflox/flox; MMTV-Cremice (#1981, #1982,
#8802), as well as in mammary tissue from 18-month old Lfngflox/flox and Lfngflox/flox; MMTV-Cre littermate mice. b-actin served as loading control.
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Figure 7. Human Basal-like and A Subset of Claudin-LowBreast Cancers Exhibit Low Levels of LFNG, HES1, andHEY1Gene Expression, but
High Levels of NOTCH1 and MYC Gene Expression
(A) Expression of selected Notch pathway genes and proliferation-associated Notch target genes in 320 breast tumors and 17 normal breast samples from the
North Carolina data set. 5 subtypes of human breast cancers are highlighted. Expression of LFNG, HES1, HEY1, MYC and NOTCH1 in basal-like breast cancers
are boxed in white and shown in enlarged view (bottom of panel A). Expression levels for these five genes in a subset of Claudin-low breast cancers (with lower
LFNG levels) are boxed in yellow. Green bars mark individual tumors showing decreased expression of all three genes (LFNG, HES1, HEY1). Red bars mark
tumors with increased expression of both NOTCH1 and MYC.
(B) Mean expression values for LFNG and NOTCH1 from the North Carolina data set. BL, basal-like; CL, Claudin-low; H2, HER2-positive; LA, luminal A; LB,
luminal B; NBL, normal breast-like. p values were calculated by comparing expression means across all subtypes.
See also Figure S5.
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BLBC shows elevated Notch signaling to proliferation/invasion
Notch target genes as well as reduced Hes/Hey expression,(D) Representative photomicrographs of anti-Caveolin-1 immunostaining in two
positive staining in blood vessels. Black arrow points to a mammary duct adjac
adipocytes and weak staining in myoepithelial cells. Scale bars correspond to 5
(E) Western blot analysis of Caveolin-2 and Phospho-IRS-1/2 in mammary tumo
See also Figure S4.together with elevated Met and InsR/Igf-1R signaling. Interest-
ingly, elevated Notch signaling and Met/Cav overexpression
could potentially also connect through induction of uPA (Leemain types of Lfngflox/flox; MMTV-Cre mammary tumors. Red arrows indicate
ent to the tumor. Note, non-tumor mammary tissues show strong staining in
0 mm.
rs (t) and non-tumor mammary tissue (n) from Lfngflox/flox; MMTV-Cre mice.
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Figure 8. Model of Cooperation between Lfng
Deficiency and Met/Caveolin Amplification/Over-
expression in Basal-like Breast Cancer
Lfng modifies Notch receptor to inhibit its activation by
Jagged ligand and enhance its activation by Dll ligand.
Loss of Lfng results in increased Jagged1-mediated
Notch activation and upregulation of c-Myc, Cyclin D1,
Igf1R and uPA, leading to increased proliferation. Loss of
Lfng may decrease Dll1-mediated Notch activation in bi-
potent mammary progenitor cells, causing expansion of
basal cells. Decreased expression of Hes/Hey Notch
target genes may de-repress the Met promoter. Selected
as cooperative event in Lfng deficiency inducedmammary
tumorigenesis, the Met/caveolin amplicon increases
abundance of Met and Caveolin1/2, the latter proteins are
predicted to enhance signaling through Igf-1R and IRS.
Signaling through Met and Igf-1R stimulate proliferation.
TGN, trans Golgi network.
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and activation of HGF (Naldini et al., 1995). The specific
combination of oncogenic mutations would therefore have the
effect of promoting a luminal progenitor fate with lower integrin
expression, and therefore reduced survival signaling from the
basement membrane. The selection for elevated Met and
InsR/Igf-1R signaling can thus provide a basal survival-type
signal for these luminal progenitor tumor cells. Thus, combina-
tion therapy targeting Notch, Met and InsR/Igf-1R or other
elements in this hybrid luminal/basal signaling network may
prove effective for treatment of BLBC with low LFNG gene
expression plus overexpression of the MET/CAV locus on
chromosome 7q31.
EXPERIMENTAL PROCEDURES
Mice
Mice were housed under standard condition and protocols approved by
animal care committees at the Hospital for Sick Children and Toronto Center
for Phenogenomics. The specific mice used for this study are described else-
where (Duncan et al., 2005; Hrabĕ de Angelis et al., 1997; Xu et al., 2010;
Zhang and Gridley, 1998). Note, the Lfng null allele was generated through
expression of Cre in the germline of female Lfngflox/+; MMTV-Cre mice.
Lfngflox/flox; MMTV-Cre experimental animals were generated by crossing
Lfngflox/flox females with Lfngflox/flox; MMTV-Cre males, which did not result in
Cre-mediated deletion in the germline.
Mammary Gland Whole-Mounts, X-Gal Staining,
Immunohistochemistry, and Western Analysis
These techniques were performed as per standard protocols and are
described in Supplemental Experimental Procedures.
Flow Cytometry and Tumor Cell Transplantation
Mouse mammary tissues were dissociated in Epicult-B medium plus collage-
nase/hyaluronidase (StemCell Technologies), and single cell suspensions
were generated according to manufacturer’s protocols. Lineage-depleted
(Lin) mammary epithelial cells were prepared using a Mouse Mammary
Stem Cell Enrichment Kit (StemCell Technologies). Lin single cells were sus-
pended in HBSS with calf serum and HEPES, and stained with saturating
concentrations of fluorochrome-conjugated antibodies as listed in Supple-638 Cancer Cell 21, 626–641, May 15, 2012 ª2012 Elsevier Inc.mental Experimental Procedures. Fluorescence was re-
corded using BD LSR-II flow cytometer and analyzed
with FlowJo 9.1 (Treestar). Dead cells were excluded
based on propidium iodide staining. Distinct populationsof tumor cells were serially diluted, suspended in matrigel, and then injected
into the mammary fat pad of 4-week-old FVB mice (Liu et al., 2007).
Array Comparative Genomic Hybridization
Genomic DNAs were purified using DNAeasy kits (QIAGEN) combined with
phenol-chloroform extraction. Array CGH was conducted at the Center for
Applied Genomics, Hospital for Sick Children. Briefly, 2.0 mg genomic DNA
was labeled using a BioPrime kit (Invitrogen), hybridized to Agilent mouse
1 3 1M CGH arrays, and scanned. Genomic DNA from non-tumor mammary
tissue of the same animal was used as reference for tumor samples.
Microarray Gene Expression Analysis
Mouse mammary tumor RNAwas purified using an RNeasy mini Kit (QIAGEN).
Microarray hybridizations were performed as described in Herschkowitz et al.
except that samples were hybridized to custom 180K Agilent microarrays
(BARCODE25503) and were scanned using an Agilent Microarray Scanner
with Feature Extraction software (Herschkowitz et al., 2007). Analysis of the
North Carolina breast cancer data set has been described (Prat et al., 2010).
See Supplemental Experimental Procedures for gene expression analysis of
mouse mammary tumors and analysis of LFNG expression in 676 human
breast cancers.
Statistics
All data are presented as mean ± standard error (SE). For two group compar-
isons, two-tailed Student’s t test was used. For fold changes compared to 1,
one-tailed one sample t test was used. A p value of 0.05 or lesswas considered
statistically significant. Mouse tumor-free survival was analyzed by the
Kaplan-Meier method and compared by a nonparametric log-rank test.
Frequency of tumor-initiating cells was calculated using L-Calc software
(StemCell Technologies).
ACCESSION NUMBERS
Transcriptional profiling data and aCGH data have been deposited in the GEO
database (http://www.ncbi.nlm.nih.gov/geo/; accession numbers GSE28712
and GSE35855, respectively).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2012.03.041.
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